Other: Research Associate, Upstream Process Development - La Jolla, California - (La Jolla, CA)

About Us aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated 3 innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr's 2 clinical-stage programs, ATYR1940 (Resolaris) and ATYR1923 (iMod.Fc), are agonists of the Resokine pathway designed to temper immune engagement in diseases characterized by excessive immune cell involvement in muscle and lung. aTyr's 3rd program, ORCA, represents a pre-clinical research program that targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.